1
|
de Mello Palma V, Frank LA, Balinha DM, Rados PV, Pohlmann AR, Guterres SS, Visioli F. Is imiquimod a promising drug to treat oral mucosa diseases? A scoping review and new perspectives. Br J Clin Pharmacol 2024; 90:427-439. [PMID: 37817570 DOI: 10.1111/bcp.15923] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Key Words] [MESH Headings] [Grants] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 06/03/2023] [Revised: 09/20/2023] [Accepted: 09/25/2023] [Indexed: 10/12/2023] Open
Abstract
Imiquimod (IMQ) is a chemotherapeutic and immunostimulant drug that is applied topically, demonstrating antitumor and antiviral activities. The objective of this review was to compile data on the off-label use of IMQ in oral mucosal diseases. IMQ has exhibited effectiveness in the treatment of various oral mucosal conditions, including oral carcinogenic lesions, neoplasms, HPV-related lesions and autoimmune disorders. Although IMQ holds promise as a potential strategy for addressing oral mucosal lesions, it is important to note that significant side effects have been frequently reported. Nonetheless, it is crucial to develop and test new technological systems, such as the combination of nanotechnology with innovative drug delivery platforms. These advancements aim to minimize side effects and prolong the drug's contact time with the mucosa, preventing its removal by salivary flow.
Collapse
Affiliation(s)
- Victor de Mello Palma
- Oral Medicine Department, School of Dentistry, Universidade Federal do Rio Grande do Sul, Porto Alegre, RS, Brazil, 90035-003
| | - Luiza Abrahão Frank
- Programa de Pós-Graduação em Ciências Farmacêuticas, Universidade Federal do Rio Grande do Sul, Porto Alegre, RS, Brazil
- Núcleo de Terapias Nanotecnológicas, Faculdade de Farmácia da Universidade Federal do Rio Grande do Sul, Porto Alegre, RS, Brazil
| | - Daiana Moraes Balinha
- Oral Medicine Department, School of Dentistry, Universidade Federal do Rio Grande do Sul, Porto Alegre, RS, Brazil, 90035-003
| | - Pantelis Varvaki Rados
- Oral Medicine Department, School of Dentistry, Universidade Federal do Rio Grande do Sul, Porto Alegre, RS, Brazil, 90035-003
| | - Adriana Raffin Pohlmann
- Programa de Pós-Graduação em Ciências Farmacêuticas, Universidade Federal do Rio Grande do Sul, Porto Alegre, RS, Brazil
- Núcleo de Terapias Nanotecnológicas, Faculdade de Farmácia da Universidade Federal do Rio Grande do Sul, Porto Alegre, RS, Brazil
| | - Silvia Stanisçuaski Guterres
- Programa de Pós-Graduação em Ciências Farmacêuticas, Universidade Federal do Rio Grande do Sul, Porto Alegre, RS, Brazil
- Núcleo de Terapias Nanotecnológicas, Faculdade de Farmácia da Universidade Federal do Rio Grande do Sul, Porto Alegre, RS, Brazil
| | - Fernanda Visioli
- Oral Medicine Department, School of Dentistry, Universidade Federal do Rio Grande do Sul, Porto Alegre, RS, Brazil, 90035-003
- Núcleo de Terapias Nanotecnológicas, Faculdade de Farmácia da Universidade Federal do Rio Grande do Sul, Porto Alegre, RS, Brazil
- Experimental Center Research, Hospital de Clínicas de Porto Alegre, Porto Alegre, RS, Brazil, 90035-903
| |
Collapse
|
2
|
Zhang X, Xie Y, Wang L. Rare Cutaneous Side Effects of Imiquimod: A Review on Its Mechanisms, Diagnosis, and Management. Dermatol Ther (Heidelb) 2023; 13:1909-1934. [PMID: 37528289 PMCID: PMC10442311 DOI: 10.1007/s13555-023-00978-0] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Key Words] [Grants] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 04/29/2023] [Accepted: 07/05/2023] [Indexed: 08/03/2023] Open
Abstract
As an immune-response modifier, imiquimod can bind to Toll-like receptors on immune cells and enhance innate and adaptive immune responses, exerting potential antitumor and antiviral effects, which led to its approval by the US Food and Drug Administration for the treatment of actinic keratosis, superficial basal cell carcinomas, and anogenital warts, and to its off-label use in treating many other benign and malignant dermatoses. Although topical administration of imiquimod has been considered well tolerated, an increasing number of cutaneous and noncutaneous side effects are being reported as its clinical applications expand. This review primarily focuses on rare cutaneous side effects. To the best of our knowledge, this is the first article to summarize the mechanism, diagnosis, and management of rare cutaneous side effects of imiquimod, which may help to heighten awareness among physicians, especially dermatologists, about potential imiquimod-induced cutaneous side effects.
Collapse
Affiliation(s)
- Xiaoyan Zhang
- Department of Dermatovenereology, West China Hospital, Sichuan University, No. 37 Guo Xue Xiang, Chengdu, 610041, Sichuan, China
| | - Yao Xie
- Department of Dermatovenereology, West China Hospital, Sichuan University, No. 37 Guo Xue Xiang, Chengdu, 610041, Sichuan, China
| | - Lin Wang
- Department of Dermatovenereology, West China Hospital, Sichuan University, No. 37 Guo Xue Xiang, Chengdu, 610041, Sichuan, China.
| |
Collapse
|
3
|
Furuoka K, Fukumoto T, Nagai H, Nishigori C. Topical imiquimod‐induced lichenoid drug reaction successfully treated with tacrolimus ointment. Dermatol Ther 2020; 33:e14480. [DOI: 10.1111/dth.14480] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 09/04/2020] [Revised: 10/11/2020] [Accepted: 10/26/2020] [Indexed: 11/30/2022]
Affiliation(s)
- Keiko Furuoka
- Division of Dermatology, Department of Internal Related Kobe University Graduate School of Medicine Kobe Japan
| | - Takeshi Fukumoto
- Division of Dermatology, Department of Internal Related Kobe University Graduate School of Medicine Kobe Japan
| | - Hiroshi Nagai
- Division of Dermatology, Department of Internal Related Kobe University Graduate School of Medicine Kobe Japan
| | - Chikako Nishigori
- Division of Dermatology, Department of Internal Related Kobe University Graduate School of Medicine Kobe Japan
| |
Collapse
|